ASX - Delayed Quote AUD

CSL Limited (CSL.AX)

273.30 -5.15 (-1.85%)
At close: April 26 at 4:10 PM GMT+10
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CSL.AX

Recent News: CSL.AX

View More
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
GlobeNewswire 3 days ago
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR Newswire 3 days ago
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?

CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
Simply Wall St. 24 days ago
10 Best Long Term ASX Stocks To Invest In

10 Best Long Term ASX Stocks To Invest In
Insider Monkey 28 days ago
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
CNW Group last month
CSL Ltd's Dividend Analysis

CSL Ltd's Dividend Analysis
GuruFocus.com last month
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season

CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
PR Newswire last month
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
Simply Wall St. 2 months ago
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
GlobeNewswire 2 months ago
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR Newswire 2 months ago
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
PR Newswire 2 months ago
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Business Wire 2 months ago
View More

Related Tickers

TLX.AX Telix Pharmaceuticals Limited
14.91
+0.20%
 
MSB.AX Mesoblast Limited
0.9300
+1.64%
 
NEU.AX Neuren Pharmaceuticals Limited
18.65
-1.06%
 
IMM.AX Immutep Limited
0.4200
-6.67%
 
CUV.AX Clinuvel Pharmaceuticals Limited
14.57
-2.80%
 
IMU.AX Imugene Limited
0.0790
-4.82%
 
PYC.AX PYC Therapeutics Limited
0.0920
-1.08%
 
OPT.AX Opthea Limited
0.6250
-7.41%
 
PAA.AX PharmAust Limited
0.2400
-4.00%
 
DXB.AX Dimerix Limited
0.3200
-4.48%